1. Li W, Dasgeb B, Phillips T, et al. Wound-healing perspectives. Dermatol Clin. 2005;23(2):181–192.
2. Lloyd DH. Healing the skin. Vet Dermatol. 1997;8(4):225.
3. Noli C, Miolo A. The mast cells in wound healing. Vet Dermatol. 2001;12(6):303–313.
4. Puxeddu I, Piliponsky AM, Bachelet I, Levi-Schaffer F. Mast cells in allergy and beyond. Int J Biochem Cell Biol. 2003;3(12)5:1601–1607.
5. Bienenstock J. Mast cell-nerve interactions: possible significance of nerve growth factor. In: Marone G, Lichtenstein LM, Galli SJ, eds. Mast Cells and Basophils. London, UK: Academic Press; 2003:313–320.
6. de Mora F, Puigdemont A, Torres R. The role of mast cells in atopy: what can we learn from canine models? A thorough review of the biology of mast cells in canine and human systems. Br J Dermatol. 2006;155(6):1109–1123.
7. Botchkarev VA, Yaar M, Peters EM, et al. Neurotrophins in skin biology and pathology. J Invest Dermatol. 2006;126(8):1719–1727.
8. Peters EM, Ericson ME, Hosoi J, et al. Neuropeptide control mechanisms in cutaneous biology: physiological and clinical significance. J Invest Dermatol. 2006;12699):1937–1947.
9. Noviana D, Mamba K, Makimura S, Horii Y. Distribution, histochemical and enzyme histochemical characterization of mast cells in dogs. J Mol Histol. 2004;35(2):123–132.
10. Noli C, Welle M, Scarampella F, Abramo F. Quantitative analysis of tryptase- and chymase-containing mast cells in eosinophilic conditions of cats. Vet Pathol. 2003;40(2):219–221
11. Artuc M, Hermes B, Steckelings UM, Grützkau A, Henz BM. Mast cells and their mediators in cutaneous wound healing-active participants or innocent bystanders? Exp Dermatol. 1999;8(1):1–16.
12. Maurer M, Theoharides T, Granstein RD. What is the physiological function of mast cells? Exp Dermatol. 2003;12(6):886–910.
13. Smith CJ, Smith JC, Finn MC. The possible role of mast cells (allergy) in the production of keloid and hypertrophic scarring. J Burn Care Rehabil. 1987;8(2):126–131.
14. Huttunen M, Aalto ML, Harvima RJ, Horsmanheimo M, Harvima IT. Alterations in mast cells showing tryptase and chymase activity in epithelializating and chronic wounds. Exp Dermatol. 2000;9(4):258–265.
15. Gottwald T, Coerper S, Schåffer M, Koveker G, Stead RH. The mast cell-nerve axis in wound healing: a hypothesis. Wound Repair Regen. 1998;6(1):8–20.
16. Schmid HH, Berdyshev EV. Cannabinoid receptor-inactive N-acylethanolamines and other fatty acid amides: metabolism and function. Prostaglandins Leukot Essent Fatty Acids. 2002;66(2-3):363–376.
17. Bisogno T, Maurelli S, Melck D, De Petrocellis L, Di Marzo V. Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes. J Biol Chem. 1997;272(6):3315–3323.
18. Ikoma A, Steinhoff M, Stander S, Yosipovitch G, Schmelz M. The neurobiology of itch. Nat Rev Neurosci. 2006;7:535–547.
19. Leung D, Saghatelian A, Simon GM, Cravatt BF.
Inactivation of N-acyl phosphatidylethanolamine phospholipase D reveals multiple mechanisms for
the biosynthesis of endocannabinoids. Biochemistry. 2006;45(15):4720–4726.
20. Berdyshev EV, Schmid PC, Dong Z, Schmid HH. Stress-induced generation of N-acylethanolamines in mouse epidermal JB6 P+ cells. Biochem J. 2000;346(Pt 2):369–374.
21. Darmani NA, Izzo AA, Degenhardt B, et al. Involvement of the cannabimimetic compound, N-palmitoylethanolamine, in inflammatory and neuropathic conditions. A review of the available pre-clinical data and first human studies. Neuropharmacol. 2005;48(8):1154–1163.
22. Valenti M, Izzo A, Darmani NA, et al. Up-regulation of levels of the cannabimimetic compound, N-palmitoylethanolamine, during some inflammatory and neuropathic conditions. Proceedings Second European Workshop on Cannabinoid Research, Busto Arsizio, Italy; 2005.
23. Lambert DM, Vandevoorde S, Jonsson KO, Fowler CJ. The palmitoylethanolamide family: a new class of anti-inflammatory agents? Curr Med Chem. 2002;9(6):663–674.
24. Re G, Barbero R, Miolo A, Di Marzo V. Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: potential use in companion animals. Vet J. 2007;173(1):21–30.
25. Aloe L, Leon A, Levi-Montalcini R. A proposed autacoid mechanism controlling mastocyte behaviour. Agents Actions. 1993;39 Spec No:C145–147.
26. Levi-Montalcini R, Skaper SD, Dal Toso R, Leon A. Nerve growth factor: from neurotrophin to neurokine. Trends Neurosci. 1996;19(11):514–520.
27. Abramo F, Noli C, Giorgi M, Leotta R, Auxilia S, Miolo A. Aliamides in veterinary dermatology: an update on mechanism of action and clinical use in dogs and cats. Selected Abstracts from the 21st ESVD Congress. Vet Dermatol. 2006;17(5):358.
28. Jack D. ALIAmides: a new approach to the treatment of inflammation. Drug News Perspect. 1996;9:93–98.
29. Miolo A, Re G, Barbero R, et al. Aliamides modulate skin mast cell degranulation in dogs and cats. J Vet Pharmacol Ther. 2006;29(Suppl 1):204–205.
30. Facci L, Dal Toso R, Romalnello S, Buriani A, Skaper SD, Leon A. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to a anandamide and palmitoylethanolamide. Proceedings of the National Academy of Sciences of the United States of America. 1995;92:3376–3380.
31. Samson MT, Small-Howard A, Shimoda LM, Koblan-Huberson M, Stokes AJ, Turner H. Differential roles of CB1 and CB2 cannabinoid receptors in mast cells. J Immunol. 2003;170(10):4953–4962.
32. Stander S, Schmelz M, Metze D, Luger T, Rukwied R. Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. J Dermatol Sci. 2005;38(3):177–188.
33. Swaim SF, Bradley DM, Spano JS. Evaluation of multipeptide–copper complex medications on open wound healing in dogs. J Am Anim Hosp Assoc. 1993;29:519–525.
34. Scarampella F, Abramo F, Noli C. Clinical and histological evaluation of an analogue of palmitoylethanolamide, PLR 120 (comicronized palmidrol INN) in cats with eosinophilic granuloma and eosinophilic plaque: a pilot study. Vet Dermatol. 2001;12(1):29–39.
35. Iba Y, Shibata A, Kato M, Masukawa T. Possible involvement of mast cells in collagen remodelling in the late phase of cutaneous wound healing in mice. Int Immunopharmacol. 2004;4(14):1873–1880.
36. Masini E, Bani D, Bigazzi M, Mannaioni PF, Bani-Sacchi T. Effects of relaxin on mast cells. In vitro and in vivo studies in rats and guinea pigs. J Clin Invest. 1994;94(5):1974–1980.
37. Nishikori Y, Kakizoe E, Kobayashi Y, Shimoura K, Okunishi H, Dekio S. Skin mast cell promotion of matrix remodeling in burn wound healing in mice: relevance of chymase. Arch Dermatol Res. 1998;290(10):553–560.
38. Janssens AS, Heide R, den Hollander JC, Mulder PG, Tank B, Oranje AP. Mast cell distribution in normal adult skin. J Clin Pathol. 2005(3);58:285–289.
39. Tsujimura T, Koshimizu U, Katoh H, Isozaki K, Kanakura Y, Tono T, et al. Mast cell number in the skin of heterozygotes reflects the molecular nature of c-kit mutation. Blood. 1993;8(10):2530–2538.
40. Galli SJ, Arizono N, Murakami T, Dvorak AM, Fox JG. Development of large numbers of mast cells at sites of idiopathic chronic dermatitis in genetically mast cell-deficient WBB6F1-W/Wv mice. Blood. 1987;69(6):1661–1666.
41. Grimbaldeston MA, Green A, Darlington S, et al. Susceptibility to basal cell carcinoma is associated with high dermal mast cell prevalence in non-sun-exposed skin for an Australian populations. Photochem Photobiol. 2003(6);78:633–639.
42. Wichmann BE. The mast cell count during the process of wound healing. Acta Pathologica et Microbiologica Scandinavica. 1955;Suppl 108):1–135.
43. Persinger MA, Lepage P, Simard JP, Parker GH. Mast cell numbers in incisional wounds in rat skin as a function of distance, time and treatment. Br J Dermatol. 1983;108(2):179–187.
44. Dvorak AM, Kissell S. Granule changes of human skin mast cells characteristic of piecemeal degranulation and associated with recovery during wound healing in situ. J Leukocyte Biol. 1991;49(2):197–210.
45. Abd-El-Aleem SA, Morgan C, Ferguson MW, McCollum CN, Ireland GW. Spatial distribution of mast cells in chronic venous leg ulcers. Eur J Histochem. 2005;49(3):265–272.
46. Claman HN, Choi KL, Sujansky W, Vatter AE. Mast cell “disappearance” in chronic murine graft-vs-host disease (GVHD)-ultrastructural demonstration of “phantom mast cells.” J Immunol. 1986;137(6):2009–20013.
47. Xiang Z, Block M, Lofman C, Nilsson G. IgE-mediated mast cell degranulation and recovery monitored by time-lapse photography. J Allergy Clin Immunol. 2001;108(1):116–121.
48. Crivellato E, Nico B, Vacca A, Ribatti D. Ultrastructural analysis of mast cell recovery after secretion by piecemeal degranulation in B-cell non-Hodgkin’s lymphoma. Leuk Lymphoma. 2003;44(3):517–521.
49. Kumamoto T, Shalhevet D, Matsue H, et al. Hair follicles serve as local reservoirs of skin mast cell precursors. Blood. 2003;102(5):1654–1660.
50. Da Silva CA, Frossard N. Potential role of stem cell factor in the asthma control by glucocorticoids. Chem Immunol Allergy. 2005;87:154–162.
51. Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54(1):1–15.
52. Weller K, Foitzik K, Paus R, Syska W, Maurer M. Mast cells are required for normal healing of skin wounds in mice. FASEB J. 2006(13):2366–2368.
53. Lambert DM, Di Marzo V. The palmitoylethanolamide and oleamide enigmas: are these two fatty acid amides cannabimimetic? Curr Med Chem. 1999;6(8):757–773.
54. Mazzari S, Canella R, Petrelli L, Marcolongo G, Leon A. N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation. Eur J Pharmacol. 1996;300(3):227–236.
55. Martin P, Leibovich SJ. Inflammatory cells during wound repair: the good, the bad, and the ugly. Trends Cell Biol. 2005;15(11):599–607.
56. Trautmann A, Toksoy A, Engelhardt E, Bröcker EB, Gillitzer R. Mast cell involvement in normal human skin wound healing: expression of monocyte chemoattractant protein-1 is correlated with recruitment of mast cells which synthesize interleukin-4 in vivo. J Pathol. 2000;190(1):100–106.
57. Hermes B, Feldmann-Böddeker I, Welker P, et al. Altered expression of mast cell chymase and tryptase and of c-Kit in human cutaneous scar tissue. J Invest Dermatol. 2000;114(1):51–55.
58. Abbott RE, Corral CJ, MacIvor DM, Lin X, Ley TJ, Mustoe TA. Augmented inflammatory responses and altered wound healing in cathepsin G-deficient mice. Arch Surg. 1998;133(9):1002–1006.
59. Abramo F, Noli C, Giorgi M, et al. Elastic fibres and mast cells in canine open skin wounds treated with an aliamide-based gel: a morphometric study. Proceedings 20th annual congress ESVD/ECVD. Vet Dermatol. 2005;16:354.
60. Mantis P, Lloyd DH, Pfeiffer D, et al. High-resolution ultrasonography of experimentally induced full-thickness canine skin wounds: Efficacy in imaging canine skin and comparison of 2 methods of measuring wound size. WOUNDS. 2005;17(5):107–113.
61. Mantis P, Lloyd DH, Pfeiffer D, et al. Assessment of the effect of an aliamide-containing topical gel by evaluation of the reduction of wound volume measured by high resolution ultrasound biomicroscopy. WOUNDS. 2007;19(5):113–119.
62. Giovannella A, Manara GL. Topical basic treatment for complicated skin wounds in dogs and cats: seven case reports. Proceedings of the Veterinary Wound Healing Association 5th Congress, Hannover, Germany, May 10–12, 2001.
63. Dabrowski R, Drobnik J. The effect of disodium cromoglycate on the skin wound healing and collagen content in the wounds of rats. Acta Physiol Pol. 1990;41(4–6):195–198.
64. Micali G, Pulvirenti N, Musumeci ML, della Valle F. Topical adelmidrol 2%, a novel aliamide, in the treatment of mild atopic dermatitis in pediatric subjects: a pilot study. J Am Acad Dermatol. 2006;54(3Suppl):AB112.
65. Badertscher K, Brönnimann M, Karlen S, Braathen LR, Yawalkar N. Mast cell chymase is increased in chronic atopic dermatitis but not in psoriasis. Arch Dermatol Res. 2005;296(10):503–506.
66. Abramovits W, Perlmutter A. Steroids versus other immune modulators in the management of allergic dermatoses. Curr Opin Allergy Clin Immunol. 2006;6(5):345–354.
67. Grove GL, Zerweck C. Efficacy of S236 (MimyX cream), a medical device cream, in promoting barrier repair of razor-induced skin trauma. Proceedings of the 64th Annual Meeting of the American Academy of Dermatology. San Francisco, CA, March 2006.
68. Kemeny L. Comparative study of S236 cream and hydrocortisone 1% in patients with atopic dermatitis. Proceedings of the 63rd Annual Meeting of the American Academy of Dermatology. New Orleans, LA, February 18–22, 2005.
69. Ständer S, Steinhoff M, Schmelz M, Weisshaar E, Metze D, Luger T. Neurophysiology of pruritus: cutaneous elicitation of itch. Arch Dermatol. 2003;139(11):1463–1470.
70. Ständer S, Reinhardt HW, Luger TA. [Topical cannabinoid agonists. An effective new possibility for treating chronic pruritus]. Hautarzt. 2006;57(9):801–807.
71. Szepietowski JC, Reich A, Szepietowski T. Emollients with endocannabinoids in the treatment of uremic pruritus: discussion of the therapeutic options. Ther Apher Dial. 2005;9(3):277–279.
72. Paus R, Schmelz M, Biró T, Steinhoff M. Frontiers in pruritus research: scratching the brain for more effective itch therapy. J Clin Invest. 2006;116(5):1174–1186.